A Retrospective Observational Study to Investigate the Prevalence of NTRK gene fusion positive in Solid Tumor in Japan

A Retrospective Observational Study to Investigate the Prevalence of NTRK gene fusion positive in Solid Tumor in Japan - An observational study to learn more about NTRK gene fusion positive in Solid Tumor in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050715

Enrollment

50000

Registered

2023-04-01

Start date

2023-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with any solid tumor and genome profiling results

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Prevalence of patients with NTRK gene fusions by patient characteristic categories, such as tumor types. Distribution of cancer types in patients with NTRK fusion positive among all, adult and pediatric	—

Countries

Japan

Contacts

Public ContactTomoyuki Taguchi

Bayer Yakuhin, Ltd. Medical Affairs & Pharmacovigilance

Tomoyuki.taguchi@bayer.com080-8525-4319

Outcome results